8-K: iTeos Therapeutics Acquired by Concentra Biosciences

iTeos Therapeutics, Inc. completes merger with Concentra Biosciences, LLC, offering shareholders $10.047 cash plus a contingent value right per share.

Summary

• iTeos Therapeutics, Inc. completed its merger with Concentra Merger Sub VIII, Inc., a wholly owned subsidiary of Concentra Biosciences, LLC, on August 29, 2025.
• The merger followed a tender offer where shareholders received $10.047 in cash per share, plus one non-transferable contractual contingent value right (CVR) per share.
• A total of 32,226,407 shares, representing approximately 72.17% of outstanding shares, were validly tendered, satisfying the minimum tender condition.
• Outstanding Company Stock Options with an exercise price less than the cash amount were canceled in exchange for cash (Cash Amount minus exercise price) and one CVR per underlying share.
• Vested Company Restricted Stock Units were canceled in exchange for the Cash Amount and one CVR.
• Unvested Company Stock Options not subject to accelerated vesting and unvested Company Restricted Stock Units not subject to accelerated vesting were canceled for no consideration.
• Trading of iTeos Therapeutics' common stock on The Nasdaq Global Market was suspended effective before the opening of trading on August 29, 2025, with delisting and deregistration processes initiated.

Sentiment

Score: 7

Explanation: The completion of the merger provides immediate cash value to shareholders and potential upside through CVRs for specific assets. However, the CVRs are highly speculative and non-transferable, and the company ceases to exist as an independent public entity, which could be seen as a loss of long-term growth potential for former shareholders.

Positives

• Shareholders received a fixed cash amount of $10.047 per share, providing immediate liquidity and a guaranteed return on a portion of their investment.
• Shareholders also received a Contingent Value Right (CVR) per share, offering potential future payments based on the disposition of specific CVR Products (EOS-984, EOS-215, and the PTPN1/2 program).
• Certain in-the-money stock options and vested restricted stock units were converted into cash and CVRs, providing value to employees and equity award holders.

Negatives

• iTeos Therapeutics ceased to be an independent publicly traded company, with its common stock delisted from Nasdaq, ending public market access for its shares.
• Former shareholders no longer participate in the future growth or strategic decisions of iTeos Therapeutics as an independent entity.
• Unvested stock options and restricted stock units not subject to accelerated vesting were canceled for no consideration, potentially impacting some employees.
• The CVRs are non-transferable, limiting liquidity for the contingent portion of the consideration and potentially reducing their market value.
• The CVR payments are highly speculative, with no assurance that holders will receive any payments, and it is possible no disposition will occur during the specified period.

Risks

• CVR payments are highly speculative and subject to numerous factors outside of Parent's control, with no assurance that holders will receive any payments.
• It is possible that no Disposition of CVR Products will occur during the 6-month Disposition Period, resulting in no CVR payments.
• The CVRs are non-transferable, which significantly limits liquidity for holders who wish to monetize their contingent rights.
• Parent and its affiliates retain full control over the CVR Products and their disposition efforts, which may not always align with maximizing CVR holder value.
• The tax treatment of CVRs and any payments received is subject to applicable law, and holders may incur tax liabilities, including potential withholding taxes.

Future Outlook

The future outlook for iTeos Therapeutics as an independent public entity is terminated. For CVR holders, the future outlook is contingent on Concentra Biosciences' ability to successfully dispose of the CVR Products (EOS-984, EOS-215, PTPN1/2 program) within the 6-month Disposition Period and realize Net Proceeds. Parent is obligated to use commercially reasonable efforts up to a $350,000 CVR Expense Cap for disposition-related activities and to seek partnerships or investments for CVR Products during this period. However, there is no assurance of any CVR payments.

Management Comments

• Parent and Merger Sub are not obligated to pursue new clinical, manufacturing or enabling work with respect to the CVR Products.
• The CVRs and the possibility of any payment hereunder with respect thereto are highly speculative and subject to numerous factors outside of Parent’s control, and there is no assurance that Holders will receive any payments under this Agreement or in connection with the CVRs.
• It is possible that no Disposition will occur during the Disposition Period and that there will not be any Gross Proceeds that may be the subject of a CVR Payment Amount.

Industry Context

This acquisition reflects a common trend in the biotechnology and pharmaceutical industry where larger entities acquire smaller, innovative firms to gain access to promising drug candidates and pipelines. The inclusion of Contingent Value Rights (CVRs) is a strategic mechanism often used to bridge valuation gaps and share future risks and rewards, particularly for early-stage or unproven assets like those of iTeos Therapeutics. This approach allows the acquirer to limit upfront cash outlay while providing target shareholders with potential upside if the acquired assets achieve specific milestones or dispositions.

Comparison to Industry Standards

• The use of Contingent Value Rights (CVRs) in biotech acquisitions is a recognized industry practice, often employed when there is significant uncertainty regarding the future value of pipeline assets. Notable examples include Sanofi's acquisition of Principia Biopharma and Bristol Myers Squibb's acquisition of Celgene, both of which included CVR components tied to specific drug development or sales milestones.
• The non-transferability of the CVRs in this transaction is a common feature in such agreements, which can limit the immediate market value and liquidity of the contingent payment compared to publicly traded CVRs (e.g., those issued in the Celgene acquisition).
• The specified 'commercially reasonable efforts' and the 'CVR Expense Cap' of $350,000 for disposition activities are standard contractual clauses. However, the relatively modest cap for disposition efforts might suggest a lower priority or limited investment in maximizing CVR value post-acquisition compared to some larger, more high-profile deals in the sector.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Received $10.047 cash per share and one non-transferable CVR per share. Lost direct equity ownership and voting rights in iTeos Therapeutics.
• Employees (with equity awards): Those with in-the-money options or vested restricted stock units received cash and CVRs. Those with unvested awards not subject to accelerated vesting had them canceled for no consideration.
• Management/Directors: Previous board members resigned. A new management team from Concentra Merger Sub VIII, Inc. was appointed to lead the Surviving Corporation.
• Concentra Biosciences, LLC: Gained full ownership and control of iTeos Therapeutics and its CVR Products, integrating them into its operations.
• Regulatory Authorities (SEC, Nasdaq): Notified of merger completion, delisting, and deregistration processes, fulfilling regulatory obligations.

Next Steps

• Nasdaq will file a Form 25 with the SEC to effect the delisting of all shares from Nasdaq and the deregistration of such shares under Section 12(b) of the Exchange Act.
• The Surviving Corporation intends to file a Form 15 with the SEC to terminate registration of the shares under Section 12(g) of the Exchange Act and suspend reporting obligations.
• Parent and its affiliates will use commercially reasonable efforts to seek and execute Disposition Agreements for CVR Products during the 6-month Disposition Period.
• Parent will make CVR payments to holders if Disposition Proceeds or Additional Closing Net Cash Proceeds are realized, subject to the terms of the CVR Agreement.

Key Dates

Keywords

iTeos Therapeutics, Concentra Biosciences, Merger, Acquisition, Tender Offer, Contingent Value Right, CVR, Delisting, Biotechnology, Oncology, EOS-984, EOS-215, PTPN1/2